Is PT-141 FDA approved? Yes, as bremelanotide (Vyleesi) for premenopausal women with HSDD. Learn what the FDA approval covers and what it does not.
Yes, PT-141 is FDA-approved, but only as bremelanotide (brand name Vyleesi) for hypoactive sexual desire disorder in premenopausal women. The FDA cleared Vyleesi in June 2019. PT-141 is not FDA-approved for men, and the research-grade vials sold online are not FDA-approved for any human use.
What PT-141 Actually Is
PT-141 is the original research code for bremelanotide, a synthetic peptide derived from alpha-melanocyte-stimulating hormone. Instead of increasing blood flow the way Viagra does, it works in the brain by activating melanocortin receptors, mainly MC4R, which are involved in sexual desire pathways.
If you are asking is bremelanotide the same as pt 141, the answer is yes — they are the same molecule. PT-141 is the code name used in early studies, and bremelanotide is the generic drug name.
The FDA-approved product is a 1.75 mg subcutaneous auto-injector, injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The label allows a maximum of one dose every 24 hours and no more than eight doses per month.
The approved indication is narrow. Acquired, generalized HSDD means low sexual desire that causes distress, was not present earlier in life, and is not better explained by another condition, medication, or relationship problem.
Is PT-141 FDA-Approved for Men?
No. Many people search is pt 141 fda approved for men, and the FDA's answer is clear: the Vyleesi label limits use to premenopausal women.
PT-141 was originally studied as a nasal spray for erectile dysfunction in men. That program was discontinued after trial participants showed increases in blood pressure, and the FDA has never approved bremelanotide for erectile dysfunction or low libido in men.
A licensed clinician can prescribe an approved drug off-label, but off-label use is not the same thing as FDA approval.
PT-141 vs. Other Options People Ask About
It helps to compare PT-141 with other products that come up in the same conversations.
| Product | FDA-approved? | Approved indication | Prescription required? |
|---|---|---|---|
| Bremelanotide (Vyleesi) | Yes | HSDD in premenopausal women | Yes |
| Sildenafil (Viagra) | Yes | Erectile dysfunction in men | Yes |
| Testosterone products | Yes | Testosterone deficiency (hypogonadism) | Yes |
| Compounded PT-141 | No | None | Varies by state |
| Research-grade PT-141 | No | None — not for human use | No |
| Semaglutide (Ozempic, Wegovy) | Yes | Type 2 diabetes; chronic weight management | Yes |
The pattern is consistent: FDA approval is tied to a specific drug, dose, and patient population, not to a molecule in general. Bremelanotide's approval does not extend to compounded versions, research peptides, or new uses.
Why Compounded and Research-Grade PT-141 Are Different
Online vendors sell PT-141 as a research chemical or a peptide for laboratory use. Those products are not FDA-approved, are not inspected for sterility or purity, and are not legal to sell as drugs or dietary supplements.
The same gap shows up across the peptide market. The answer to is aod-9604 fda approved is no, and it has no approved human indication in the United States.
Unregulated peptides have caused dosing errors and injection-site infections, and an unregulated vial may contain a different amount of drug than the label claims.
How to Check FDA Approval Status Yourself
You do not have to trust a vendor's marketing page. The FDA publishes approval information in free, searchable databases:
- Drugs@FDA — official approval letters, labels, and review documents.
- Orange Book — approved drug products and therapeutic equivalence ratings.
- DailyMed — current prescribing information from the manufacturer.
Searching bremelanotide returns Vyleesi, while searching PT-141 often returns nothing because that is a research code rather than an approved brand or generic name. For comparison, is semaglutide fda-approved? Yes — but for type 2 diabetes and chronic weight management, not for HSDD.
Safety, Side Effects, and Who Should Avoid It
Vyleesi is generally tolerated but not side-effect free. In clinical trials, the most common reactions were nausea, flushing, headache, and injection-site reactions.
Blood pressure can rise temporarily after a dose, which is why the label lists uncontrolled hypertension and known cardiovascular disease as contraindications. Other warnings include focal hyperpigmentation — dark patches on the skin, gums, or genitals — and nausea severe enough to need antiemetic treatment.
Bremelanotide is not approved for postmenopausal women, and it is not recommended during pregnancy. It is also not a controlled substance under federal law, but that does not make it risk-free.
Anyone considering PT-141 should review their medical history, medications, and cardiovascular risk with a licensed healthcare professional. Peptides bought online without a prescription should never be assumed to be safe or equivalent to the approved product.
Frequently Asked Questions
Is PT-141 FDA-approved for men?
No. The FDA approved bremelanotide (Vyleesi) only for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The original male erectile dysfunction program was discontinued over blood pressure concerns, and no male indication has ever been approved.
Is bremelanotide the same as PT-141?
Yes. PT-141 is the research code name and bremelanotide is the generic drug name for the same peptide. The FDA-approved brand is Vyleesi, a 1.75 mg subcutaneous auto-injector used on demand.
Can I buy FDA-approved PT-141 online without a prescription?
No. Vyleesi is prescription-only and requires an evaluation by a licensed clinician. Peptides marketed online as research chemicals are not FDA-approved, are not made under FDA manufacturing standards, and should not be injected.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.